SG11201903892UA - [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors - Google Patents
[1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitorsInfo
- Publication number
- SG11201903892UA SG11201903892UA SG11201903892UA SG11201903892UA SG11201903892UA SG 11201903892U A SG11201903892U A SG 11201903892UA SG 11201903892U A SG11201903892U A SG 11201903892UA SG 11201903892U A SG11201903892U A SG 11201903892UA SG 11201903892U A SG11201903892U A SG 11201903892UA
- Authority
- SG
- Singapore
- Prior art keywords
- beerse
- turnhoutseweg
- janssen pharmaceutica
- international
- janssen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16196924 | 2016-11-02 | ||
PCT/EP2017/077910 WO2018083098A1 (en) | 2016-11-02 | 2017-10-31 | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903892UA true SG11201903892UA (en) | 2019-05-30 |
Family
ID=57240919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903892UA SG11201903892UA (en) | 2016-11-02 | 2017-10-31 | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors |
Country Status (18)
Country | Link |
---|---|
US (1) | US10947242B2 (es) |
EP (1) | EP3535267B1 (es) |
JP (1) | JP7076441B2 (es) |
KR (1) | KR20190070972A (es) |
CN (1) | CN109923116B (es) |
AR (1) | AR110026A1 (es) |
AU (1) | AU2017353310B2 (es) |
BR (1) | BR112019008404A2 (es) |
CA (1) | CA3041412A1 (es) |
EA (1) | EA039788B1 (es) |
ES (1) | ES2864131T3 (es) |
IL (1) | IL266305B (es) |
MX (1) | MX2019005154A (es) |
MY (1) | MY193511A (es) |
SG (1) | SG11201903892UA (es) |
TW (1) | TWI764950B (es) |
UA (1) | UA125302C2 (es) |
WO (1) | WO2018083098A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017076900A1 (en) | 2015-11-02 | 2017-05-11 | Janssen Pharmaceutica Nv | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND |
WO2018083101A1 (en) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors |
JP7021208B2 (ja) * | 2016-11-02 | 2022-02-16 | ヤンセン ファーマシューティカ エヌ.ベー. | PDE2阻害剤としての[1,2,4]トリアゾロ[1,5-a]ピリミジン化合物 |
CN109923116B (zh) | 2016-11-02 | 2022-12-06 | 詹森药业有限公司 | 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶衍生物 |
US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
CA3188639A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06509069A (ja) | 1991-06-27 | 1994-10-13 | バージニア・コモンウェルス・ユニバーシティ | シグマレセプターリガンドおよびその用途 |
AU745425B2 (en) | 1998-01-27 | 2002-03-21 | Aventis Pharmaceuticals Inc. | Substituted oxoazaheterocyclyl factor Xa inhibitors |
US6194410B1 (en) | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
ES2324293T3 (es) | 2002-10-03 | 2009-08-04 | Vertex Pharmaceuticals Incorporated | Derivados de piperacina y piperidina para el tratamiento de enfermedades neurologicas. |
EP1644003A1 (en) | 2003-06-04 | 2006-04-12 | Vernalis (Cambridge) Limited | Triazolo ´1,5-a!pyrimidines and their use in medicine |
JP2007526894A (ja) | 2003-07-16 | 2007-09-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | グリコーゲンシンターゼキナーゼ3インヒビターとしてのトリアゾロピリミジン誘導体 |
KR20060105872A (ko) | 2003-12-29 | 2006-10-11 | 반유 세이야꾸 가부시끼가이샤 | 신규한 2-헤테로아릴 치환된 벤즈이미다졸 유도체 |
AR051092A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa |
MX2007003319A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
WO2007113136A1 (de) | 2006-03-30 | 2007-10-11 | Basf Aktiengesellschaft | Verwendung von substituierten riazolopyrimidinen zur bekämpfung von phyto pathogenen schadpilzen |
JP2007332061A (ja) | 2006-06-14 | 2007-12-27 | Nippon Kayaku Co Ltd | 新規ピラゾロ[1,5−a]ピリミジン誘導体及びその用途 |
US8153803B2 (en) | 2006-07-18 | 2012-04-10 | The General Hospital Corporation | Compositions and methods for modulating sirtuin activity |
US7928103B2 (en) | 2006-10-17 | 2011-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
US8138168B1 (en) | 2007-09-26 | 2012-03-20 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑的2-芳基咪唑衍生物 |
JP2014503528A (ja) | 2010-12-14 | 2014-02-13 | エレクトロプホレトイクス リミテッド | カゼインキナーゼ1δ(CK1δ)阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用 |
AU2012221828C1 (en) | 2011-02-23 | 2015-10-01 | Pfizer Inc. | Imidazo[5,1-f][1,2,4]triazines for treatment of neurological disorders |
US10604523B2 (en) | 2011-06-27 | 2020-03-31 | Janssen Pharmaceutica Nv | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives |
EP2758375A1 (en) | 2011-09-23 | 2014-07-30 | Advinus Therapeutics Limited | Amide compounds, compositions and applications thereof |
US9034882B2 (en) | 2012-03-05 | 2015-05-19 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
ES2676224T3 (es) | 2012-03-09 | 2018-07-17 | Lexicon Pharmaceuticals, Inc. | Compuestos a base de pirazolo[1,5-a]pirimidina, composiciones que los comprenden y métodos para usarlos |
AU2015223049B2 (en) | 2014-02-27 | 2019-03-21 | Merck Patent Gmbh | Heterocyclic compounds as NaV channel inhibitors and uses thereof |
DK3119772T3 (da) | 2014-03-19 | 2019-08-26 | Boehringer Ingelheim Int | Heteroaryl syk-hæmmere |
SG11201606216UA (en) * | 2014-04-23 | 2016-09-29 | Dart Neuroscience Llc | Substituted [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds as pde2 inhibitors |
MD20160112A2 (ro) * | 2014-04-25 | 2017-06-30 | Pfizer Inc. | Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1 |
CN105566321B (zh) | 2014-10-29 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
US10239882B2 (en) * | 2014-11-05 | 2019-03-26 | Dart Neuroscience (Cayman) Ltd. | Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors |
TWI530688B (zh) * | 2014-11-18 | 2016-04-21 | 彭顯智 | 製備微奈米探針設備及方法 |
CN105753817A (zh) | 2015-01-01 | 2016-07-13 | 成都贝斯凯瑞生物科技有限公司 | 一类取代氮杂环衍生物及其应用 |
WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
CA3001857A1 (en) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
WO2017076900A1 (en) | 2015-11-02 | 2017-05-11 | Janssen Pharmaceutica Nv | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND |
CN105898377A (zh) * | 2015-12-11 | 2016-08-24 | 乐视网信息技术(北京)股份有限公司 | 用户终端、服务器及弹幕加载方法、系统 |
WO2017157882A1 (en) | 2016-03-14 | 2017-09-21 | Université Catholique de Louvain | Serine biosynthetic pathway inhibitors |
CN109923116B (zh) | 2016-11-02 | 2022-12-06 | 詹森药业有限公司 | 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶衍生物 |
JP7021208B2 (ja) | 2016-11-02 | 2022-02-16 | ヤンセン ファーマシューティカ エヌ.ベー. | PDE2阻害剤としての[1,2,4]トリアゾロ[1,5-a]ピリミジン化合物 |
WO2018083101A1 (en) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors |
EP3555094A1 (en) | 2016-12-16 | 2019-10-23 | Janssen Pharmaceutica NV | Bicyclic oga inhibitor compounds |
-
2017
- 2017-10-31 CN CN201780067759.3A patent/CN109923116B/zh active Active
- 2017-10-31 BR BR112019008404A patent/BR112019008404A2/pt active Search and Examination
- 2017-10-31 KR KR1020197015232A patent/KR20190070972A/ko active IP Right Grant
- 2017-10-31 ES ES17792066T patent/ES2864131T3/es active Active
- 2017-10-31 AU AU2017353310A patent/AU2017353310B2/en not_active Ceased
- 2017-10-31 UA UAA201906027A patent/UA125302C2/uk unknown
- 2017-10-31 SG SG11201903892UA patent/SG11201903892UA/en unknown
- 2017-10-31 EA EA201991109A patent/EA039788B1/ru unknown
- 2017-10-31 US US16/346,730 patent/US10947242B2/en active Active
- 2017-10-31 TW TW106137541A patent/TWI764950B/zh not_active IP Right Cessation
- 2017-10-31 WO PCT/EP2017/077910 patent/WO2018083098A1/en active Application Filing
- 2017-10-31 CA CA3041412A patent/CA3041412A1/en active Pending
- 2017-10-31 EP EP17792066.7A patent/EP3535267B1/en active Active
- 2017-10-31 MY MYPI2019002499A patent/MY193511A/en unknown
- 2017-10-31 MX MX2019005154A patent/MX2019005154A/es unknown
- 2017-10-31 JP JP2019522892A patent/JP7076441B2/ja active Active
- 2017-11-02 AR ARP170103037A patent/AR110026A1/es unknown
-
2019
- 2019-04-29 IL IL266305A patent/IL266305B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3535267A1 (en) | 2019-09-11 |
ES2864131T3 (es) | 2021-10-13 |
WO2018083098A1 (en) | 2018-05-11 |
AU2017353310B2 (en) | 2021-08-12 |
UA125302C2 (uk) | 2022-02-16 |
IL266305A (en) | 2019-06-30 |
EP3535267B1 (en) | 2020-12-30 |
AU2017353310A1 (en) | 2019-05-16 |
CN109923116B (zh) | 2022-12-06 |
KR20190070972A (ko) | 2019-06-21 |
US20190276462A1 (en) | 2019-09-12 |
CN109923116A (zh) | 2019-06-21 |
IL266305B (en) | 2021-10-31 |
JP7076441B2 (ja) | 2022-05-27 |
MX2019005154A (es) | 2019-06-20 |
TWI764950B (zh) | 2022-05-21 |
TW201831486A (zh) | 2018-09-01 |
EA201991109A1 (ru) | 2019-09-30 |
EA039788B1 (ru) | 2022-03-14 |
BR112019008404A2 (pt) | 2019-09-17 |
CA3041412A1 (en) | 2018-05-11 |
JP2019532985A (ja) | 2019-11-14 |
MY193511A (en) | 2022-10-17 |
AR110026A1 (es) | 2019-02-13 |
US10947242B2 (en) | 2021-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903892UA (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201901141WA (en) | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201811643TA (en) | Compounds and methods for modulating rna function | |
SG11201810485SA (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
SG11201810018TA (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
SG11201906958TA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
SG11201903770UA (en) | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders | |
SG11201806852PA (en) | Protein purification |